VERIGRAFT, a Swedish biotechnology pioneer in regenerative medicine, has secured a €1.2 million Eurostars grant to revolutionize vascular surgery through advanced 3D printed arterial grafts. The PREPPER (PREcision Printed PERsonalized Tissue Therapies) project brings together expertise from multiple institutions, including Swiss-based Readily3D SA, Swedish research institute RISE, and Sahlgrenska University Hospital.
Addressing Critical Medical Challenges
Current synthetic vascular grafts face significant limitations, including poor integration and high failure rates that compromise patient outcomes. The PREPPER project aims to overcome these challenges by developing personalized grafts that more closely mimic natural arterial function and structure. This innovative approach combines cutting-edge 3D printing technology, solution-blown fiber techniques, and advanced tissue engineering principles.
Innovation in Bioengineering
"This Eurostars grant is a major milestone for VERIGRAFT and regenerative medicine. With PREPPER, we are accelerating the future of personalized tissue therapies," stated Dr. Raimund Strehl, Chief Technology Officer at VERIGRAFT. The project's timing is particularly significant, as the global vascular graft market is expected to surpass $4 billion by 2026, highlighting the urgent need for improved solutions.
Research Infrastructure and Collaboration
VERIGRAFT, established in 2014, operates state-of-the-art preclinical laboratories near Gothenburg University, positioning itself at the heart of Sweden's medical research community. The company's strategic location near one of Sweden's largest hospitals facilitates close collaboration with clinical researchers and maintains strong international partnerships across Europe, Asia, and the United States.
Future Applications and Impact
The PREPPER project's scope extends beyond vascular grafts, potentially influencing broader applications in regenerative medicine. By focusing on enhanced biocompatibility and integration properties, the research could pave the way for engineered tissues across various medical applications. The project's success could position Europe at the forefront of 3D bioprinting and regenerative medicine innovation, marking a significant advancement in personalized medical treatments.
